Description

(Dual Agonist: GLP-1R / GIPR)

GLP-1T  is a synthetic dual incretin receptor agonist that simultaneously activates the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). This dual-pathway mechanism has been extensively investigated for its synergistic effects on glucose control, insulin sensitivity, lipid metabolism, and energy regulation in research models.

By combining the metabolic actions of both GLP-1 and GIP signaling, Tirzepatide represents an advanced next-generation incretin analog designed to explore multihormonal regulation of glucose and body-weight dynamics.

---

Mechanism of Action (Based on Preclinical and Clinical Research):

• GLP-1R activation: Enhances insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety.

• GIPR activation: Supports insulin response and lipid metabolism while complementing GLP-1–mediated effects.

• Dual incretin synergy: Integrates complementary hormonal pathways to optimize metabolic outcomes.

• Energy expenditure modulation: Improves thermogenesis and fat oxidation in experimental settings.

• Cardiometabolic regulation: Demonstrates potential benefits on lipid profiles and inflammatory markers.

---

Potential Benefits (Based on Preclinical Research):

• Significant reduction in body-weight gain in obesity research models

• Improved insulin sensitivity and glucose tolerance

• Favorable effects on lipid metabolism and energy efficiency

• Enhanced appetite control and caloric balance

• Studied for applications in obesity, diabetes, and metabolic-syndrome research

---

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.